Small cell lung cancer: diagnosis and management

1 Views
administrator
administrator
07/08/23

Small cell lung cancer, which occurs almost exclusively in smokers, is a malignancy characterised by rapid doubling time, high growth fraction and widespread metastasis at presentation. In this presentation, we will briefly discuss the classification of pulmonary Neuro-endocrine tumours by the World Health Organisation followed by a detailed discussion of the clinical features, lab evaluation and management of SCLC, both limited and extended stage. The frontline therapy in small cell lung cancer is etoposide and cisplatin along with thoracic radiotherapy and prophylactic cranial irradiation in patients who have a good response to therapy. Hyperfractionation of radiotherapy may provide some benefit but is also associated with increase incidence of complications. Newer agents for SCLC include Vandetanib and immunotherapy molecules, such as Iplimumab and nivolumab.

Check out our other videos

Ascites
https://www.youtube.com/watch?v=Uvl8UCwSUI4

Aplastic anemia
https://www.youtube.com/watch?v=OlAMqP-El8c

Acute kidney injury
https://www.youtube.com/watch?v=73QwSB6JuNA

Cardio renal syndrome
https://youtu.be/6KKDpAVkBK4

Vasculitis: Causes, clinical features and management
https://youtu.be/lCLK7RWlJts

Dengue fever: clinical features and management
https://youtu.be/VNQV8KgT3-Q

Addisonโ€™s disease
https://youtu.be/JVKycyaSvIk

Hepatopulmonary syndrome
https://youtu.be/uu50uWjR-rg

Osteoporosis
https://youtu.be/RP5OOb5zQd4

Hypertensive emergencies
https://youtu.be/kmNcV4Zxljo

Hepatorenal syndrome
https://youtu.be/QvP0AcoWjuw

Approach to a case of Anemia
https://youtu.be/ElL-yYKHgW0

Meningitis and Encephalitis
https://youtu.be/6rE19sE6GR8

We would like to thank the following resources:

Royalty free stock images from
www.pexels.com

Professional powerpoint templates by
Creative Venus Youtube channel

Initial smoke stock royalty free footage from
www.videezy.com

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next